LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

5 result(s)
Filter and sort
5 result(s)
Journal Article > CommentaryFull Text

Leishmaniasis in Syria – A call for action of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) study groups for infections in travellers and migrants (ESGITM) and for clinical parasitology (ESGCP)

Travel Med Infect Dis. 2 April 2025; Online ahead of print; 102849.; DOI:10.1016/j.tmaid.2025.102849
Abbara A, González-Sanz M, AlKharrat A, Khalife M, Elferruh Y,  et al.
Travel Med Infect Dis. 2 April 2025; Online ahead of print; 102849.; DOI:10.1016/j.tmaid.2025.102849
Journal Article > ResearchFull Text

Ambulatory Multi-Drug Resistant Tuberculosis Treatment Outcomes in a Cohort of HIV-Infected Patients in a Slum Setting in Mumbai, India

PLOS One. 1 December 2011; Volume 6 (Issue 12); DOI:10.1371/journal.pone.0028066
Isaakidis P, Cox HS, Varghese B, Montaldo C, Da Silva E,  et al.
PLOS One. 1 December 2011; Volume 6 (Issue 12); DOI:10.1371/journal.pone.0028066
India carries one quarter of the global burden of multi-drug resistant TB (MDR-TB) and has an estimated 2.5 million people living with HIV. Despite this reality, provision of treatment for MDR-TB is extremely limited, particularly for HIV-infected individuals. Médecins Sans Frontières (MSF) has been treating HIV-infected MDR-TB patients in Mumbai since May 2007. This is the first report of treatment outcomes among HIV-infected MDR-TB patients in India.More
Journal Article > EditorialFull Text

QT prolongation for old and new drugs: how much should we really worry?

Int J Tuberc Lung Dis. 1 April 2022; Volume 26 (Issue 4); 298-301.; DOI:10.5588/ijtld.22.0072
Motta I, Cozzi SN, Pontali E
Int J Tuberc Lung Dis. 1 April 2022; Volume 26 (Issue 4); 298-301.; DOI:10.5588/ijtld.22.0072
Journal Article > ResearchFull Text

MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network

Int J Infect Dis. 1 February 2020; Volume 92; DOI:10.1016/j.ijid.2020.01.042
Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM,  et al.
Int J Infect Dis. 1 February 2020; Volume 92; DOI:10.1016/j.ijid.2020.01.042
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians and public health staff with an updated and easy-to-consult document arising from consensus of Global Tuberculosis Network (GTN) experts. The core published documents and guidelines have been reviewed including the recently published MDR-TB WHO rapid advice and ATS/CDC/ERS/IDSA guidelines. After a rapid review of epidemiology and risk factors, the clinical priorities on MDR-TB diagnosis (including whole genome sequencing and drug-susceptibility testing interpretations) and treatment (treatment design and management, TB in children) are discussed. Furthermore, the review comprehensively describes the latest information on contact tracing and LTBI management in MDR-TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB sequelae, infection control and other public health priorities.More
Journal Article > CommentaryFull Text

Clinical standards for the assessment, management and rehabilitation of post-TB lung disease

Int J Tuberc Lung Dis. 1 October 2021; Volume 25 (Issue 10); 797-813.; DOI: 10.5588/ijtld.21.0425
Migliori GB, Marx FM, Ambrosino N, Zampogna E, Schaaf HS,  et al.
Int J Tuberc Lung Dis. 1 October 2021; Volume 25 (Issue 10); 797-813.; DOI: 10.5588/ijtld.21.0425
BACKGROUND
Increasing evidence suggests that post-TB lung disease (PTLD) causes significant morbidity and mortality. The aim of these clinical standards is to provide guidance on the assessment and management of PTLD and the implementation of pulmonary rehabilitation (PR).

METHODS
A panel of global experts in the field of TB care and PR was identified; 62 participated in a Delphi process. A 5-point Likert scale was used to score the initial ideas for standards and after several rounds of revision the document was approved (with 100% agreement).

RESULTS
Five clinical standards were defined: Standard 1, to assess patients at the end of TB treatment for PTLD (with adaptation for children and specific settings/situations); Standard 2, to identify patients with PTLD for PR; Standard 3, tailoring the PR programme to patient needs and the local setting; Standard 4, to evaluate the effectiveness of PR; and Standard 5, to conduct education and counselling. Standard 6 addresses public health aspects of PTLD and outcomes due to PR.

CONCLUSION
This is the first consensus-based set of Clinical Standards for PTLD. Our aim is to improve patient care and quality of life by guiding clinicians, programme managers and public health officers in planning and implementing adequate measures to assess and manage PTLD.
More